MA50449A - Inhibiteurs d'il-8 destinés à être utilisés dans le traitement de certains sarcomes - Google Patents

Inhibiteurs d'il-8 destinés à être utilisés dans le traitement de certains sarcomes

Info

Publication number
MA50449A
MA50449A MA050449A MA50449A MA50449A MA 50449 A MA50449 A MA 50449A MA 050449 A MA050449 A MA 050449A MA 50449 A MA50449 A MA 50449A MA 50449 A MA50449 A MA 50449A
Authority
MA
Morocco
Prior art keywords
inhibitors
treatment
certain sarcomas
sarcomas
certain
Prior art date
Application number
MA050449A
Other languages
English (en)
Inventor
Laura Brandolini
Ryan David Roberts
Original Assignee
Dompe Farm Spa
The Res Institute At Nationwide Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompe Farm Spa, The Res Institute At Nationwide Childrens Hospital filed Critical Dompe Farm Spa
Publication of MA50449A publication Critical patent/MA50449A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA050449A 2017-10-24 2018-10-23 Inhibiteurs d'il-8 destinés à être utilisés dans le traitement de certains sarcomes MA50449A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17198072.5A EP3476390A1 (fr) 2017-10-24 2017-10-24 Inhibiteurs il-8 destinés à être utilisés dans le traitement de sarcomes

Publications (1)

Publication Number Publication Date
MA50449A true MA50449A (fr) 2020-09-02

Family

ID=60162145

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050449A MA50449A (fr) 2017-10-24 2018-10-23 Inhibiteurs d'il-8 destinés à être utilisés dans le traitement de certains sarcomes

Country Status (11)

Country Link
US (2) US11660291B2 (fr)
EP (2) EP3476390A1 (fr)
JP (2) JP2021500413A (fr)
KR (2) KR20200091405A (fr)
AU (1) AU2018356497B2 (fr)
BR (1) BR112020007940A2 (fr)
CA (1) CA3079781A1 (fr)
IL (1) IL274031B2 (fr)
MA (1) MA50449A (fr)
SG (1) SG11202003622TA (fr)
WO (1) WO2019081470A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102017220539A1 (de) 2017-11-17 2019-05-23 Zf Friedrichshafen Ag Verfahren zum Betreiben eines Systems aus einem landwirtschaftlichen Arbeitsfahrzeug und zumindest einem an diesem angeordneten Arbeitsgerät

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1303249B1 (it) 1998-10-23 2000-11-06 Dompe Spa Alcune n-(2-aril-propionil)-solfonammidi e preparazionifarmaceutiche che le contengono.
US20030096781A1 (en) * 2001-08-31 2003-05-22 University Of Southern California IL-8 is an autocrine growth factor and a surrogate marker for Kaposi's sarcoma
EP1776336B1 (fr) 2004-03-23 2009-09-30 DOMPE' pha.r.ma s.p.a. Derives de l'acide 2-phenylpropionique et compositions pharmaceutiques contenant lesdits derives
EP2166006A1 (fr) * 2008-09-18 2010-03-24 Dompe' S.P.A. Acides 2-aryl-propioniques et dérivés et compositions pharmaceutiques les contenant
PL2356462T3 (pl) 2008-11-11 2017-07-31 The Regents Of The University Of Michigan Kompozycje anty-CXCR1 oraz sposoby
US10561676B2 (en) 2013-08-02 2020-02-18 Syntrix Biosystems Inc. Method for treating cancer using dual antagonists of CXCR1 and CXCR2
MA41044A (fr) * 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
US20170165363A1 (en) * 2015-12-11 2017-06-15 The Johns Hopkins University Cancer cell migration inhibitors and their use in therapeutic treatments
SI3402474T1 (sl) 2016-01-15 2021-12-31 Dompe Farmaceutici S.P.A. IL-8 inhibitorji za uporabo pri zdravljenju s kemoterapijo povzročene periferne neuropatije
US10660909B2 (en) * 2016-11-17 2020-05-26 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists

Also Published As

Publication number Publication date
JP2023164916A (ja) 2023-11-14
US11660291B2 (en) 2023-05-30
US20210361627A1 (en) 2021-11-25
IL274031B2 (en) 2023-06-01
RU2020116757A3 (fr) 2021-11-30
IL274031A (en) 2020-06-30
BR112020007940A2 (pt) 2020-10-20
CA3079781A1 (fr) 2019-05-02
EP3476390A1 (fr) 2019-05-01
JP2021500413A (ja) 2021-01-07
KR20230156797A (ko) 2023-11-14
AU2018356497B2 (en) 2024-02-29
SG11202003622TA (en) 2020-05-28
KR20200091405A (ko) 2020-07-30
EP3700514A1 (fr) 2020-09-02
US20230248704A1 (en) 2023-08-10
AU2018356497A1 (en) 2020-06-11
RU2020116757A (ru) 2021-11-30
WO2019081470A1 (fr) 2019-05-02

Similar Documents

Publication Publication Date Title
DK3731772T3 (da) Systems for the treatment of disease states and disorders
DK3743053T3 (da) Anvendelse af cannabinoider i behandling af epilepsi
MA47688A (fr) Compositions utiles dans le traitement de l'amyotrophie spinale
MA49760A (fr) Mavacamten destiné à être utilisé dans le traitement de la cardiomyopathie hypertrophique
FR24C1010I1 (fr) Modulateurs des récepteurs p2x3 et p2x2/3 de diaminopyrimidine destinés à être utilisés dans le traitement de la toux
MA44676A (fr) Compositions de disulfure de sélénium destinées à être utilisées dans le traitement du dysfonctionnement de la glande de meibomius
MA52219A (fr) Traitement de l'hidradénite suppurée à l'aide d'inhibiteurs de jak
MA49248A (fr) Inhibiteurs de fgfr2 utilisés dans le traitement du cholangiocarcinome
DK3681500T3 (da) Anvendelse af pilocarpinhydrochlorid til behandling af presbyopi
MA50233A (fr) Mic-1 et glp-1 destinés à être utilisés dans le traitement de l'obésité
DK3668513T3 (da) Pyruvatkinase-aktiveringsmidler til anvendelse til behandling af blodsygdomme
FR3032353B1 (fr) Composition pharmaceutique et dispositif pour le traitement de la douleur
MA43825A (fr) Schémas posologiques pour le traitement d'infections fongiques
IT201600121601A1 (it) Composizione orale per il trattamento del reflusso gastroesofageo e del reflusso laringo-faringeo
MA55821A (fr) Antagonistes 5-ht2a destinés à être utilisés dans le traitement de la dépression
MA43861A (fr) Inhibiteurs il-8 destinés à être utilisés dans le traitement d'une neuropathie périphérique induite par une chimiothérapie
MA49524A (fr) Compositions d'antagoniste de nk-1 et méthodes destinées à être utilisées dans le traitement de la dépression
MA47111A (fr) Agents ciblant sirpgamma destinés à être utilisés dans le traitement du cancer
MA45226A (fr) Compositions et méthodes de traitement ou de prévention d'affections liées à l'oxalate
MA45552A (fr) Compositions destinées au traitement de l'amylose
MA45973A (fr) Combinaisons d'inhibiteurs de btk pour le traitement du myélome multiple
MA54290A (fr) Inhibiteur de kinase aurora a destiné à être utilisé dans le traitement du neuroblastome
DK3365329T3 (da) Nurr1:rxr aktiverende forbindelser til samtidig behandling af symptomer og patologi for parkinsons sygge
MA51128A (fr) Inhibiteurs c5ar destinés à être utilisés dans le traitement de la douleur iatrogène induite par la chimiothérapie
MA42985A (fr) Traitement de troubles liés à l'acide biliaire